Nanocomposites for neurodegenerative diseases: Hydrogel-nanoparticle combinations for a challenging drug delivery

International Journal of Artificial Organs

Volumn 34, Issue 12, 2011, Pages 1115-1127

  Giordano, Carmen ^a   Albani, Diego ^b   Gloria, Antonio ^c   Tunesi, Marta ^a   Rodilossi, Serena ^b   Russo, Teresa ^c   Forloni, Gianluigi ^b   Ambrosio, Luigi ^c   Cigada, Alberto ^a  

^a POLITECNICO DI MILANO   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CNR   (Italy)

Author keywords

Alzheimer's disease; Hydrogels; Intranasal delivery; Nanocomposites; Nanoparticles; Nanotoxicity; Parkinson's disease

Indexed keywords

BIOCHEMISTRY; BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; NANOCOMPOSITES; NANOPARTICLES; NEURODEGENERATIVE DISEASES; TARGETED DRUG DELIVERY;

ALZHEIMERS DISEASE; DEVELOPED COUNTRIES; HEALTHCARE SYSTEMS; HYDROGEL NANOPARTICLES; INTRANASAL; INTRANASAL DELIVERY; NANOTOXICITY; NEURODEGENERATIVE; NEURODEGENERATIVE DISORDERS; PARKINSON'S DISEASE;

HYDROGELS;

NANOCOMPOSITE; NANOPARTICLE; NERVE GROWTH FACTOR; POLYBUTYL CYANOACRYLATE; POLYMER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; HEALTH CARE COST; HYDROGEL; IN VIVO STUDY; MOUSE; NANOTECHNOLOGY; NANOTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PREVALENCE; REVIEW; RISK ASSESSMENT; SURFACE PLASMON RESONANCE; TOXICITY; TRANSGENIC MOUSE;

EID: 84455195432     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.2011.8915     Document Type: Review

References (89)

1. Cutting Edge Info Reports. Neurodegenerative market forecast to 2013 (Report TA222). 2009. Available at: http://www.cuttingedgeinfo.com/research/market-intelligence/neurodegenerative-forecast/. Accessed December 5, 2011.
2. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009;11:e22. doi: 10.1017/S1462399409001148
3. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord. 2003;18(1):19-31.
4. Waldau B, Shetty AK. Behavior of neural stem cells in the Alzheimer brain. Cell Mol Life Sci. 2008;65(15):2372-2384.
5. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631-639.
6. Giordano C, Albani D, Gloria A, et al. Multidisciplinary perspectives for Alzheimer's and Parkinson's diseases: hydrogels for protein delivery and cell-based drug delivery as therapeutic strategies. Int J Artif Organs. 2009;32(12):836-850.
7. Aridon P, Geraci F, Turturici G, D'Amelio M, Savettieri G, Sconzo G. Protective role of heat shock proteins in Parkinson's disease. Neurodegener Dis. 2011;8(4):155-168.
8. Laskowska E, Matuszewska E, Kuczyńska-Wiśnik D. Small heat shock proteins and protein-misfolding diseases. Curr Pharm Biotechnol. 2010;11(2):146-157.
9. Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm. 2006;314(2):120-126.
10. Gloria A, De Santis R, Ambrosio L. Polymer-based composite scaffolds for tissue engineering. J Appl Biomater Biomech. 2010;8(2):57-67.
11. Sionkowka A. Current research on the blends of natural and synthetic polymers as new biomaterials: review. Prog Polym Sci. 2011;36(9):1254-1276.
12. Gloria A, Russo T, De Santis R, Ambrosio L. 3D fiber deposition technique to make multifunctional and tailor-made scaffolds for tissue engineering applications. J Appl Biomater Biomech. 2009;7(3):141-152.
13. Schwartz MM. Composite materials handbook. New York, NY: McGraw-Hill, 1992.
14. Mallick PK. Composites engineering handbook. New York, NY: CRC Press, 1997.
15. Jones RM. Mechanics of composite materials. London: Taylor & Francis, 1999.
16. Nicolais L, Gloria A, Ambrosio L. The mechanics of biocomposites. In: Ambrosio L, ed. Biomedical composites. London: CRC Press, 2010; 411-440.
17. Gloria A, Ronca D, Russo T, et al. Technical features and criteria in designing fiber-reinforced composite materials: from the aerospace and aeronautical field to biomedical applications. J Appl Biomater Biomech. 2011;9(2):151-163.
18. Kabiri K, Zohuriaan-Mehr MJ. Porous superabsorbent hydrogel composites: synthesis, morphology and swelling rate. Macromol Mater Eng. 2004;289(7):653-661.
19. Schapery RA. Thermal expansion coefficients of composite materials based on energy principles. J Comp Mat. 1968;2(3):380-404.
20. Nicolais L. Mechanics of composites. Polym Eng Sci. 1975;15(3):137-149.
21. Nicolais L, Narkis M. Stress-strain behaviour of styrene-acrylonitrile/ glass bead composites in the glassy region. Polym Eng Sci. 1971;11(3):194-199.
22. Russo T, Gloria A, D'Antò V, et al. Poly(e-caprolactone) reinforced with sol-gel synthesized organic-inorganic hybrid fillers as composite substrates for tissue engineering. J Appl Biomater Biomech. 2010;8(3):146-152.
23. Alfieri I, Lorenzi A, Montenero A, Gnappi G, Fiori F. Sol-gel silicon alkoxides-polyethylene glycol derived hybrids for drug delivery systems. J Appl Biomater Biomech. 2010;8(1):14-19.
24. Catauro M, Verardi D, Melisi D, Belotti F, Mustarelli P. Novel sol-gel organic-inorganic hybrid materials for drug delivery. J Appl Biomater Biomech. 2010;8(1):42-51.
25. Lamponi S, Forbicioni M, Barbucci R. The role of fibronectin in cell adhesion to spiral patterned TiO2 nanoparticles. J Appl Biomater Biomech. 2009;7(2):104-110.
26. Sandin K, Kloo L, Odselius R, Ollsson LF. The observation of nano-crystalline calcium phosphate precipitate in a simple supersaturated inorganic blood serum model -composition and morphology. J Appl Biomater Biomech. 2009;7(1):13-22.
27. Zaffe D, Traversa G, Mozzati M, Morelli F, D'Angeli G. Behavior of aqueous nanocrystalline hydroxyapatite in oral bone regeneration. J Appl Biomater Biomech. 2011;9(1):19-25.
28. Yang L, Zhang L, Webster TJ. Nanobiomaterials: state of the art and future trends. Adv Eng Mat. 2011;13(6):B197-217.
29. Camargo PH, Satyanarayana KG, Wypych F. Nanocomposites: synthesis, structure, properties and new application opportunities. Mat Res. 2009;12:1-39.
30. Liao K, Ren Y, Xiao T. Single-walled carbon nanotubes in epoxy composites. In: Mai YW, Yu ZZ, eds. Polymer nanocomposites. Cambridge: Woodhead, 2006.
31. Pietronave S, Iafisco M, Locarno D, Rimondini L, Prat M. Functionalized nanomaterials for diagnosis and therapy of cancer. J Appl Biomater Biomech. 2009;7(2):77-89.
32. Dvir T, Timko BP, Kohane DS, Langer R. Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol 2011;6(1):13-22.
33. Fu AH, Micheel CM, Cha J, Chang H, Yang H, Alivisatos AP. Discrete nanostructures of quantum dots/Au with DNA. J Am Chem Soc. 2004;126(35):10832-10833.
34. Yin Y. Alivisatos AP. Colloidal nanocrystal synthesis and the organic-inorganic interface. Nature. 2005;437(7059):664-670.
35. Cozzoli PD, Pellegrino T, Manna L. Synthesis, properties and perspectives of hybrid nanocrystal structures. Chem Soc Rev. 2006;35(11):1195-1208.
36. Srivastava S, Samanta B, Arumugam P, Han G, Rotello VM. DNA-mediated assembly of iron platinum (FePt) nanoparticles. J Mater Chem. 2007;17:52-55.
37. Quarta A, Di Corato R, Manna L, Ragusa A, Pellegrino T. Fluorescent-magnetic hybrid nanostructures: preparation, properties, and applications in biology. IEEE Trans Nanobioscience. 2007;6(4):298-308.
38. Paul DR, Robeson LM. Polymer nanotechnology: nanocomposites. Polymer. 2008;49(15):3187-3204.
39. Raffaini G, Ganazzoli F. Protein adsorption on biomaterial and nanomaterial surfaces: a molecular modelling approach to study non-covalent interactions. J Appl Biomater Biomech. 2010;8(3):135-145.
40. De Santis R, Gloria A, Russo T, et al. A basic approach toward the development of nanocomposite magnetic scaffolds for advanced bone tissue engineering. J Appl Pol Sci. 2011;122(6):3599-3605.
41. Giannoni P, Narcisi R. Nano-approaches in cartilage repair. J Appl Biomater Biomech. 2009;7(1):1-12.
42. Satarkar NS, Biswal D, Hilt JZ. Hydrogel nanocomposites: a review of applications as remote controlled biomaterials. Soft Matter. 2010;6:2364-2371.
43. Fischer H. Polymer nanocomposites: from fundamental research to specific applications. Mater Sci Eng. 2003;23(6-8):763-772.
44. Gloria A, De Santis R, Ambrosio L, Causa F, Tanner KE. A multi-component fiber-reinforced PHEMA-based hydrogel/ HAPEX™ device for customized intervertebral disc prosthesis. J Biomat Appl. 2011;25(8):795-810.
45. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release. 2005;108(2-3):193-214.
46. Nahar M, Dutta T, Murugesan S, et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Syst. 2006;23(4):259-318.
47. Zhong Y, Bellamkonda RV. Biomaterials for the central nervous system. J R Soc Interface. 2008;5(26):957-975.
48. Mittal G, Carswell H, Brett R, Currie S, Kumar MN. Development and evaluation of polymer nanoparticles for oral deliv-ery of estradiol to rat brain in a model of Alzheimer's pathology. J Control Release. 2011;150(2):220-228.
49. Carroll RT, Bhatia D, Geldenhuys W, et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target. 2010;18(9):665-674.
50. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm. 2010;389(1-2):207-212.
51. Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. Int J Pharm. 2011;415(1-2):273-283.
52. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target. 2009;17(8):564-574.
53. Bhaskar S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010;7:3.
54. Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;7(5):521-540.
55. Yang J, Wadghiri YZ, Hoang DM, et al. Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage. 2011;55(4):1600-1609.
56. Härtig W, Kacza J, Paulke BR, et al. In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. Eur J Neurosci. 2010;31(1):99-109.
57. Orive G, De Castro M, Kong HJ, et al. Bioactive cell-hydrogel microcapsules for cell-based drug delivery. J Control Release. 2009;135(3):203-210.
58. Lee KR, Maeng HJ, Chae JB, et al. Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: potential involvement of transporters in the pathway. Drug Metab Pharmacokinet. 2010;25(5):430-441.
59. Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008;58(3):287-297.
60. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Nose-to-brain delivery of tacrine. J Pharm Pharmacol. 2007;59(9):1199-1205.
61. Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm. 2007;335(1-2):138-146.
62. Kim TK, Kang W, Chun IK, Oh SY, Lee YH, Gwak HS. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur J Pharm Sci. 2009;38(5):525-532.
63. Luppi B, Bigucci F, Corace G, et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci. 2011;44(4):559-565.
64. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-tobrain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7(12):4169-4176.
65. Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release. 2011;151(2):131-138.
66. Xia H, Gao X, Gu G, et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials. 2011;32(36):9888-9898.
67. Cheng Q, Feng J, Chen J, Zhu X, Li F. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm Drug Dispos. 2008;29(8):431-439.
68. Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765-774.
69. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation and characterization of proteinloaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release. 2006;111(1-2):107-116.
70. Goycoolea FM, Lollo G, Remuñán-López C, Quaglia F, Alonso MJ. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules. 2009;10(7):1736-1743.
71. Bednar MM. Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease. Drugs. 2009;12(9):566-575.
72. Alsarra IA, Hamed AY, Alanazi FK, Neau SH. Rheological and mucoadhesive characterization of poly(vinylpyrrolidone) hydrogels designed for nasal mucosal drug delivery. Arch Pharm Res. 2011;34(4):573-582.
73. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2(4):MR17-MR71.
74. Suh WH, Suslick KS, Stucky DG, Suh YH. Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol. 2009;87(3):133-170.
75. Billi F, Campbell P. Nanotoxicology of metal wear particles in total joint arthroplasty: a review of current concepts. J Appl Biomater Biomech. 2010;8(1):1-6.
76. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta. 2011;1810(3):361-373.
77. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1-9.
78. Yang Z, Liu Z.W, Allaker RP, et al. A review of nanoparticle functionality and toxicity on the central nervous system. J R Soc Interface. 2010;7:S411-S422.
79. Yang Z, Zhang Y, Yang Y, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine. 2010;6(3):427-441.
80. Fraser TW, Reinardy HC, Shaw BJ, Henry TB, Handy RD. Dietary toxicity of single-walled carbon nanotubes and fullerenes (C60) in rainbow trout (Oncorhynchus mykiss). Nanotoxicology. 2011;5(1):98-108.
81. Nyitrai G, Kékesi O, Pál I, et al. Assessing toxicity of polyamidoamine dendrimers by neuronal signaling functions. Nanotoxicology 2011. [Epub ahead of print].
82. Zhang L, Bai R, Liu Y, et al. The dose-dependent toxicological effects and potential perturbation on the neurotransmitter secretion in brain following intranasal instillation of copper nanoparticles. Nanotoxicology 2011. [Epub ahead of print].
83. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol. 2010;40(4):328-346.
84. Batelli S, Albani D, Rametta R, et al. DJ-1 modulates alphasynuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One. 2008;3(4):e1884.
85. Albani D, Polito L, Batelli S, et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem. 2009;110(5):1445-1456.
86. Kyriakidou K, Lucarini G, Zizzi A, et al. Dynamic co-seeding of osteoblast and endothelial cells on 3D polycaprolactone scaffolds for enhanced bone tissue engineering. J Bioact Compat Pol. 2008;23(3):227-243.
87. Gloria A, Causa F, De Santis R, Netti PA, Ambrosio L. Dynamic-mechanical properties of a novel composite intervertebral disc prosthesis. J Mater Sci Mater Med. 2007;18(11):2159-2165.
88. Gloria A, Manto L, De Santis R, Ambrosio L. Biomechanical behavior of a novel composite intervertebral body fusion device. J Appl Biomat Biomech. 2008;6(3):163-169.
89. De Santis R, Gloria A, Sano H, et al. Effect of light curing and dark reaction phases on the thermomechanical properties of a Bis-GMA based dental restorative material. J Appl Biomat Biomech. 2009;7(2):132-140.